Article
News
Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
Author(s):
Key Takeaways
- Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries starting January 2025.
- The solution has secured coverage across all US Medicaid programs and 60% of commercial insurance providers, enhancing access for chronic dry eye disease treatment.
Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to the dry eye disease treatment for millions of patients, particularly older adults.
(Image credit: Adobe Stock/Avve Diana)
Harrow announced new market access achievements in the 2025 Medicare Part D Prescription Drug Program.
According to the company, effective January 1, 2025, cyclosporine ophthalmic solution 0.1% (Vevye) will be included on key formularies managed by major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors represent more than 25 million Medicare Part D beneficiaries.
In addition to Medicare Part D, Vevye has secured coverage across other major insurance programs, including all US Medicaid programs and 60% of commercial insurance providers. According to Harrow, this broad coverage underscores the company’s commitment to ensuring access to effective treatment for chronic dry eye disease (DED) across insurance types, a condition that affects millions of Americans, particularly older adults.1
Mark L. Baum, chairman and CEO of Harrow, said the company was pleased to have achieved expanded access to the solution for Medicare beneficiaries.
“For too long, these patients have lacked an accessible, effective, and well-tolerated treatment for dry eye,” he said. “With 67 million Medicare beneficiaries in the United States—54 million of whom have Medicare Part D coverage—there is substantial demand for the clinical benefits Vevye provides. The prevalence of DED increases with age, and this chronic condition poses a greater risk to seniors, affecting their comfort, vision, and overall quality of life. Expanded access will allow us to better serve Medicare beneficiaries, enhancing their eye health, independence, and quality of life.”
Cyclosporine ophthalmic solution 0.1% (Vevye) is a patented, preservative-free, twice-daily (BID) prescription eye drop based on a “water-free” semifluorinated alkane technology. Uniquely dispensed in a 10-µL drop, it is the first and only cyclosporine-based product indicated for both the signs and symptoms of dry eye disease.
Reference
1. Anon. Harrow Announces Market Access Wins for VEVYE. Business Wire. Published November 12, 2024. Accessed November 12, 2024. https://www.businesswire.com/news/home/20241112120889/en/Harrow-Announces-Market-Access-Wins-for-VEVYE%C2%AE
